Finance Research
yassmr73h7
gileadsciencesincnasdaqgsgild_ciqreportlandscape.rtf_.dot
Gilead Sciences Inc. (NasdaqGS:GILD)
Gilead Sciences Inc. (NasdaqGS:GILD)
Date Created: Mar-21-2016
Copyright © 2016, S&P Capital IQ, a part of McGraw Hill Financial.
Page 1 of 1
Date Created: Mar-21-2016
Page 1 of 1
Company Status
Operating
Website
www.gilead.com
Primary Industry
Biotechnology
Number of Employees
8,000
Year Founded
1987
Primary Office Location
333 Lakeside Drive Foster City, California 94404 United States Main Phone: 650-574-3000 Main Fax: 650-578-9264
Business Description / Color Notes
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Key Financials
In Millions of the trading currency, except per share items.
For the Fiscal Period Ending
12 months Dec-31-2013
12 months Dec-31-2014
12 months Dec-31-2015
12 months Dec-31-2016
12 months Dec-31-2017
12 months Dec-31-2018
Currency
USD
USD
USD
USD
USD
USD
Total Revenue
11,202.0
24,890.0
32,639.0
31,552.91
30,988.35
29,834.96
Growth Over Prior Year
15.5%
122.2%
31.1%
(3.33%)
(1.79%)
(3.72%)
Gross Profit
8,343.0
21,102.0
28,633.0
Margin %
74.5%
84.8%
87.7%
88.73%
89.05%
89.94%
EBITDA
4,869.0
16,665.0
23,291.0
22,530.01
21,727.68
20,506.88
Margin %
43.5%
67.0%
71.4%
71.40%
70.12%
68.73%
EBIT
4,524.0
15,615.0
22,193.0
21,415.82
20,613.58
19,353.44
Margin %
40.4%
62.7%
68.0%
67.87%
66.52%
64.87%
Earnings from Cont. Ops.
3,057.0
12,059.0
18,106.0
Margin %
27.3%
48.4%
55.5%
Net Income
3,075.0
12,101.0
18,108.0
17,154.08
16,608.80
15,652.84
Margin %
27.5%
48.6%
55.5%
54.37%
53.60%
52.46%
Diluted EPS Excl. Extra Items³
1.81
7.35
11.91
12.24
12.48
12.60
Growth Over Prior Year
10.4%
306.1%
62.0%
(2.92%)
1.92%
1.02%
Current Capitalization
Currency
USD
Share Price
$ 90.27
Shares Out.
1,366.8
Market Capitalization
123,385.2
- Cash & Short Term Investments
14,607.0
+ Total Debt
22,178.0
+ Pref. Equity
+ Total Minority Interest
579.0
= Total Enterprise Value (TEV)
__________ 131,535.2
Book Value of Common Equity
18,536.0
+ Pref. Equity
+ Total Minority Interest
579.0
+ Total Debt
22,178.0
= Total Capital
__________ 41,293.0
*Includes number of shares outstanding + shares held by non-controlling interest holders without accounting for dilutive securities
Valuation Multiples based on Current Capitalization
For the Fiscal Period Ending
12 months Dec-31-2014
12 months Dec-31-2015
12 months Dec-31-2016
12 months Dec-31-2017
12 months Dec-31-2018
TEV/Total Revenue
5.3x
4.0x
4.27x
4.35x
4.52x
TEV/EBITDA
7.9x
5.6x
5.98x
6.20x
6.57x
TEV/EBIT
8.4x
5.9x
6.30x
6.54x
6.97x
P/Diluted EPS Before Extra
12.3x
7.6x
7.57x
7.43x
7.35x
P/BV
8.8x
6.9x
3.95x
3.20x
3.18x
Price/Tang BV
42.3x
18.0x
Public Ownership Summary
Type
Common Stock Equivalent Held
% of Total Shares Outstanding
Market Value (USD in mm)
Institutions
1,172,772,039
85.80
108,680.8
Individuals/Insiders
8,976,322
0.66
831.8
Public and Other
185,097,330
13.54
17,153.0
Total
1,366,845,691
100.00
126,665.6
Top 25 Holders
Holder
Common Stock Equivalent Held
% of CSO
Market Value (USD in mm)
BlackRock, Inc. (NYSE:BLK)
91,214,072
6.673
8,233.9
The Vanguard Group, Inc.
85,547,536
6.259
7,722.4
Fidelity Investments
71,864,392
5.258
6,487.2
Capital Research and Management Company
68,140,709
4.985
6,151.1
State Street Global Advisors, Inc.
57,920,194
4.238
5,228.5
T. Rowe Price Group, Inc. (NasdaqGS:TROW)
39,227,288
2.870
3,541.0
J.P. Morgan Asset Management, Inc.
19,751,296
1.445
1,782.9
BNY Mellon Asset Management
19,135,778
1.400
1,727.4
Northern Trust Global Investments
18,861,072
1.380
1,702.6
UBS Asset Management
15,768,061
1.154
1,423.4
Teachers Insurance and Annuity Association of America - College Retirement Equities Fund
14,661,755
1.073
1,323.5
Wellington Management Group LLP
12,933,219
0.946
1,167.5
Norges Bank Investment Management
12,928,294
0.946
1,167.0
Temasek Holdings (Private) Limited
12,794,924
0.936
1,155.0
Invesco PowerShares Capital Management LLC
12,735,679
0.932
1,149.6
Franklin Resources, Inc. (NYSE:BEN)
12,451,935
0.911
1,124.0
Geode Capital Management, LLC
12,249,341
0.896
1,105.7
AllianceBernstein L.P.
11,960,103
0.875
1,079.6
Morgan Stanley, Investment Banking and Brokerage Investments
10,330,135
0.756
932.5
OppenheimerFunds, Inc.
9,261,694
0.678
836.1
American Century Investment Management Inc.
7,800,505
0.571
704.2
Walter Scott & Partners Limited
7,240,668
0.530
653.6
Invesco Ltd. (NYSE:IVZ)
6,861,839
0.502
619.4
Robeco Investment Management Inc.
6,843,182
0.501
617.7
Goldman Sachs Group, Investment Banking and Securities Investments
6,751,587
0.494
609.5
All Others
536,513,103
39.252
48,431.0
Total
1,181,748,361
86.458
106,676.4
Top 25 Holders (Institutions)
Holder
Common Stock Equivalent Held
% of CSO
Market Value (USD in mm)
BlackRock, Inc. (NYSE:BLK)
91,214,072
6.673
8,233.9
The Vanguard Group, Inc.
85,547,536
6.259
7,722.4
Fidelity Investments
71,864,392
5.258
6,487.2
Capital Research and Management Company
68,140,709
4.985
6,151.1
State Street Global Advisors, Inc.
57,920,194
4.238
5,228.5
T. Rowe Price Group, Inc. (NasdaqGS:TROW)
39,227,288
2.870
3,541.0
J.P. Morgan Asset Management, Inc.
19,751,296
1.445
1,782.9
BNY Mellon Asset Management
19,135,778
1.400
1,727.4
Northern Trust Global Investments
18,861,072
1.380
1,702.6
UBS Asset Management
15,768,061
1.154
1,423.4
Teachers Insurance and Annuity Association of America - College Retirement Equities Fund
14,661,755
1.073
1,323.5
Wellington Management Group LLP
12,933,219
0.946
1,167.5
Norges Bank Investment Management
12,928,294
0.946
1,167.0
Temasek Holdings (Private) Limited
12,794,924
0.936
1,155.0
Invesco PowerShares Capital Management LLC
12,735,679
0.932
1,149.6
Franklin Resources, Inc. (NYSE:BEN)
12,451,935
0.911
1,124.0
Geode Capital Management, LLC
12,249,341
0.896
1,105.7
AllianceBernstein L.P.
11,960,103
0.875
1,079.6
Morgan Stanley, Investment Banking and Brokerage Investments
10,330,135
0.756
932.5
OppenheimerFunds, Inc.
9,261,694
0.678
836.1
American Century Investment Management Inc.
7,800,505
0.571
704.2
Walter Scott & Partners Limited
7,240,668
0.530
653.6
Invesco Ltd. (NYSE:IVZ)
6,861,839
0.502
619.4
Robeco Investment Management Inc.
6,843,182
0.501
617.7
Goldman Sachs Group, Investment Banking and Securities Investments
6,751,587
0.494
609.5
All Others
527,536,781
38.595
47,620.7
Total
1,172,772,039
85.801
105,866.1
Top 25 Holders (Individuals/Insiders)
Holder
Position
Common Stock Equivalent Held
% of CSO
Market Value (USD in mm)
Martin Ph.D., John C.
Executive Chairman
4,019,727
0.294
362.9
Bischofberger Ph.D., Norbert W.
Chief Scientific Officer and Executive Vice President of Research & Development
2,341,621
0.171
211.4
Milligan Ph.D., John F.
Chief Executive Officer, President and Director
1,058,963
0.077
95.6
Davignon, Vicomte Étienne
Independent Director and Member of Nominating & Corporate Governance Committee
837,605
0.061
75.6
Alton, Gregg H.
Executive Vice President of Corporate & Medical Affairs and Secretary
147,090
0.011
13.3
Washington, Robin L.
Chief Financial Officer and Executive Vice President
134,172
0.010
12.1
Wilson, Gayle Edlund
Independent Director, Chairman of Nominating & Corporate Governance Committee and Member of Scientific Committee
103,873
0.008
9.4
Wold-Olsen MBA, Per
Independent Director, Member of Compensation Committee and Member of Scientific Committee
90,077
0.007
8.1
Carter, Paul Rutherford
Executive Vice President of Commercial Operations
61,122
0.004
5.5
Lofton FACHE, Kevin E.
Independent Director, Member of Audit Committee and Member of Compensation Committee
45,692
0.003
4.1
Cogan Ph.D., John F.
Lead Independent Director, Member of Audit Committee and Member of Scientific Committee
44,309
0.003
4.0
Hills, Carla Anderson
Independent Director and Member of Nominating & Corporate Governance Committee
37,819
0.003
3.4
Whitley M.D., Ph.D., Richard J.
Independent Director, Member of Independent Health Policy Advisory Board, Chairman of Scientific Committee and Member of Nominating & Corporate Governance Committee
23,669
0.002
2.1
Madigan, John W.
Independent Director, Chairman of Compensation Committee and Member of Audit Committee
15,295
0.001
1.4
Moore, Nicholas G.
Independent Director, Chairman of Audit Committee and Member of Compensation Committee
15,288
0.001
1.4
Total
8,976,322
0.657
810.3
Top 25 Holders (By Funds)
Holder
Common Stock Equivalent Held
% of CSO
Market Value (USD in mm)
Vanguard Index Funds - Vanguard Total Stock Market ETF (ARCA:VTI)
27,504,499
2.012
2,482.8
The Growth Fund of America (MutualFund:AGRB.X)
25,173,741
1.842
2,272.4
Vanguard Index Funds - Vanguard S&P 500 ETF (ARCA:VOO)
17,954,510
1.314
1,620.8
Fidelity Contrafund (MutualFund:FCNT.X)
16,586,088
1.213
1,497.2
Vanguard Institutional Index Funds-Vanguard Institutional Index Fund (MutualFund:VIII.X)
15,786,511
1.155
1,425.0
The Investment Company of America (MutualFund:AICB.X)
15,072,391
1.103
1,360.6
SPDR S&P 500 ETF Trust (ARCA:SPY)
14,502,612
1.061
1,309.2
Capital World Growth and Income Fund (MutualFund:CWGI.X)
12,313,531
0.901
1,111.5
Government Pension Fund Global
11,057,318
0.809
998.1
PowerShares QQQ Trust, Series 1 (NasdaqGM:QQQ)
10,722,298
0.784
967.9
Vanguard Index Funds - Vanguard Growth ETF (ARCA:VUG)
8,197,058
0.600
739.9
Fidelity Concord Street Trust - Spartan 500 Index Fund (MutualFund:FUSE.X)
7,205,763
0.527
650.5
The Select Sector SPDR Trust - The Health Care Select Sector SPDR Fund (ARCA:XLV)
7,007,495
0.513
632.6
Fidelity Capital Trust - Fidelity Capital Appreciation Fund (MutualFund:FCAK.X)
6,299,178
0.461
568.6
Fidelity Select Portfolios - Biotechnology Portfolio (MutualFund:FBIO.X)
6,160,326
0.451
556.1
T. Rowe Price Growth Stock Fund, Inc. (MutualFund:PRGF.X)
5,965,700
0.436
538.5
Amcap Fund (MutualFund:AMPF.X)
5,820,726
0.426
525.4
iShares Trust - iShares Nasdaq Biotechnology ETF (NasdaqGM:IBB)
5,706,995
0.418
515.2
American Funds Insurance Series - Growth-Income Fund
5,627,700
0.412
508.0
iShares Trust - iShares Core S&P 500 ETF (ARCA:IVV)
5,578,794
0.408
503.6
College Retirement Equities Fund - CREF Stock Account
5,407,853
0.396
488.2
T. Rowe Price Blue Chip Growth Fund, Inc. (MutualFund:TRBC.X)
5,248,900
0.384
473.8
Fidelity Mt. Vernon Street Trust - Fidelity Growth Company Fund (MutualFund:FDGR.X)
5,177,494
0.379
467.4
T. Rowe Price Health Sciences Fund, Inc. (MutualFund:PRHS.X)
4,202,930
0.307
379.4
iShares Trust - iShares Russell 1000 Growth ETF (ARCA:IWF)
4,168,426
0.305
376.3
All Others
374,803,306
27.421
33,833.5
Total
629,252,143
46.037
56,802.6
Top Buyers
Buyer
Common Stock Equivalent Held
Change
Ethenea Independent Investors S.A.
2,820,000
2,820,000
Societe Generale, Securities Investments
3,692,447
2,583,268
Skandinaviska Enskilda Banken AB, Private Banking, Investment Banking, and Insurance Arm
2,520,460
2,520,460
Deutsche Bank, Private Banking and Investment Banking Investments
5,296,544
2,066,391
Renaissance Technologies Corp.
2,319,448
2,039,148
Top Sellers
Seller
Common Stock Equivalent Held
Change
Capital Research and Management Company
68,140,709
(17,399,671)
Fidelity Investments
71,864,392
(7,339,776)
Mellon Capital Management Corporation
0
(3,882,163)
Susquehanna International Group, LLP, Asset Management Arm
2,241,397
(3,012,098)
Jennison Associates LLC
219,681
(2,561,694)
Insider Trading Activity Summary
Last 3 Months
Transactions
Shares
# of Purchases
8
# of Shares Purchased
489,543
# of Sales
17
# of Shares Sold
740,219
Net Transactions
(9)
Net Sales
(250,676)
Last 6 Months
Transactions
Shares
# of Purchases
11
# of Shares Purchased
497,431
# of Sales
47
# of Shares Sold
1,826,565
Net Transactions
(36)
Net Sales
(1,329,134)
Recent Insider Purchases (Last 6 Months)
Holder Name
Position
Trade Date Range
Transacted Shares
Transaction Value (USD in mm)
Price Range
Moore, Nicholas G.
Independent Director, Chairman of Audit Committee and Member of Compensation Committee
Mar-01-2016
169
-
-
Washington, Robin L.
Chief Financial Officer and Executive Vice President
Feb-23-2016
28,280
0
-
Martin Ph.D., John C.
Executive Chairman
Feb-15-2016 - Feb-16-2016
194,562
18,854
76.02
Bischofberger Ph.D., Norbert W.
Chief Scientific Officer and Executive Vice President of Research & Development
Feb-15-2016 - Feb-16-2016
67,488
18,854
76.02
Milligan Ph.D., John F.
Chief Executive Officer, President and Director
Feb-15-2016 - Feb-16-2016
75,288
18,854
76.02
Alton, Gregg H.
Executive Vice President of Corporate & Medical Affairs and Secretary
Feb-15-2016 - Feb-16-2016
55,454
18,854
76.02
Washington, Robin L.
Chief Financial Officer and Executive Vice President
Feb-15-2016 - Feb-16-2016
48,568
18,854
76.02
Carter, Paul Rutherford
Executive Vice President of Commercial Operations
Feb-15-2016 - Feb-16-2016
19,734
18,854
76.02
Wilson, Gayle Edlund
Independent Director, Chairman of Nominating & Corporate Governance Committee and Member of Scientific Committee
Dec-01-2015
2,104
0
-
Washington, Robin L.
Chief Financial Officer and Executive Vice President
Nov-09-2015
2,892
-
-
Washington, Robin L.
Chief Financial Officer and Executive Vice President
Nov-05-2015
2,892
0
-
Recent Insider Sales (Last 6 Months)
Holder Name
Position
Trade Date Range
Transacted Shares
Transaction Value (USD in mm)
Price Range
Alton, Gregg H.
Executive Vice President of Corporate & Medical Affairs and Secretary
Mar-14-2016
(5,000)
(450,000)
90.00
Martin Ph.D., John C.
Executive Chairman
Mar-01-2016
(100,000)
(7,218,354)
16.40 - 88.86
Milligan Ph.D., John F.
Chief Executive Officer, President and Director
Mar-01-2016
(112,000)
(7,996,755)
16.40 - 87.79
Carter, Paul Rutherford
Executive Vice President of Commercial Operations
Mar-01-2016
(2,000)
(125,990)
24.91 - 87.90
Wilson, Gayle Edlund
Independent Director, Chairman of Nominating & Corporate Governance Committee and Member of Scientific Committee
Feb-26-2016
(6,650)
(464,868)
20.71 - 90.61
Washington, Robin L.
Chief Financial Officer and Executive Vice President
Feb-23-2016
(28,280)
0
-
Martin Ph.D., John C.
Executive Chairman
Feb-16-2016
(122,901)
(11,207,342)
91.19
Bischofberger Ph.D., Norbert W.
Chief Scientific Officer and Executive Vice President of Research & Development
Feb-16-2016
(40,716)
(3,711,263)
91.15
Milligan Ph.D., John F.
Chief Executive Officer, President and Director
Feb-16-2016
(45,433)
(4,141,218)
91.15
Alton, Gregg H.
Executive Vice President of Corporate & Medical Affairs and Secretary
Feb-16-2016
(32,786)
(2,988,444)
91.15
Washington, Robin L.
Chief Financial Officer and Executive Vice President
Feb-16-2016
(26,808)
(2,443,549)
91.15
Washington, Robin L.
Chief Financial Officer and Executive Vice President
Feb-16-2016
(6,250)
(567,000)
90.72
Carter, Paul Rutherford
Executive Vice President of Commercial Operations
Feb-16-2016
(7,395)
(674,054)
91.15
Martin Ph.D., John C.
Executive Chairman
Feb-01-2016
(100,000)
(6,702,975)
16.40 - 84.35
Carter, Paul Rutherford
Executive Vice President of Commercial Operations
Feb-01-2016
(2,000)
(86,369)
24.91 - 82.32
Martin Ph.D., John C.
Executive Chairman
Jan-04-2016
(100,000)
(8,128,208)
16.40 - 99.49
Carter, Paul Rutherford
Executive Vice President of Commercial Operations
Jan-04-2016
(2,000)
(146,874)
24.91 - 99.20
Bischofberger Ph.D., Norbert W.
Chief Scientific Officer and Executive Vice President of Research & Development
Dec-15-2015
(70,000)
(5,629,179)
19.09 - 102.66
Milligan Ph.D., John F.
Chief Executive Officer, President and Director
Dec-07-2015
(100,000)
(8,867,727)
14.50 - 103.56
Martin Ph.D., John C.
Executive Chairman
Dec-01-2015
(150,000)
(13,698,092)
14.50 - 107.01
Alton, Gregg H.
Executive Vice President of Corporate & Medical Affairs and Secretary
Dec-01-2015
(2,000)
(213,907)
106.54 - 107.18
Alton, Gregg H.
Executive Vice President of Corporate & Medical Affairs and Secretary
Dec-01-2015
(10,000)
(815,301)
24.30 - 106.54
Carter, Paul Rutherford
Executive Vice President of Commercial Operations
Dec-01-2015
(2,000)
(158,780)
26.99 - 106.38
Whitley M.D., Ph.D., Richard J.
Independent Director, Member of Independent Health Policy Advisory Board, Chairman of Scientific Committee and Member of Nominating & Corporate Governance Committee
Nov-24-2015
(7,050)
0
-
Cogan Ph.D., John F.
Lead Independent Director, Member of Audit Committee and Member of Scientific Committee
Nov-24-2015
(15,000)
(1,278,615)
20.71 - 105.95
Whitley M.D., Ph.D., Richard J.
Independent Director, Member of Independent Health Policy Advisory Board, Chairman of Scientific Committee and Member of Nominating & Corporate Governance Committee
Nov-20-2015 - Nov-24-2015
(8,546)
(914,757)
106.48 - 107.18
Bischofberger Ph.D., Norbert W.
Chief Scientific Officer and Executive Vice President of Research & Development
Nov-16-2015
(70,000)
(5,522,569)
23.76 - 103.79
Milligan Ph.D., John F.
Chief Executive Officer, President and Director
Nov-09-2015
(100,000)
(9,315,394)
14.50 - 108.27
Washington, Robin L.
Chief Financial Officer and Executive Vice President
Nov-09-2015
(2,892)
-
-
Washington, Robin L.
Chief Financial Officer and Executive Vice President
Nov-05-2015
(3,108)
(335,136)
107.83
Bischofberger Ph.D., Norbert W.
Chief Scientific Officer and Executive Vice President of Research & Development
Nov-03-2015
(5,000)
0
-
Martin Ph.D., John C.
Executive Chairman
Nov-02-2015
(150,000)
(14,237,651)
14.50 - 109.58
Alton, Gregg H.
Executive Vice President of Corporate & Medical Affairs and Secretary
Nov-02-2015
(2,000)
(219,332)
109.67
Alton, Gregg H.
Executive Vice President of Corporate & Medical Affairs and Secretary
Nov-02-2015
(10,000)
(850,225)
24.30 - 109.67
Washington, Robin L.
Chief Financial Officer and Executive Vice President
Nov-02-2015
(6,250)
(684,150)
109.13 - 109.61
Carter, Paul Rutherford
Executive Vice President of Commercial Operations
Nov-02-2015
(2,000)
(138,089)
26.99 - 108.36
Cogan Ph.D., John F.
Lead Independent Director, Member of Audit Committee and Member of Scientific Committee
Oct-27-2015
(15,000)
(1,339,425)
20.71 - 110.00
Alton, Gregg H.
Executive Vice President of Corporate & Medical Affairs and Secretary
Oct-26-2015
(5,000)
(428,525)
24.30 - 110.00
Cogan Ph.D., John F.
Lead Independent Director, Member of Audit Committee and Member of Scientific Committee
Oct-26-2015
(15,000)
(1,339,425)
20.71 - 110.00
Carter, Paul Rutherford
Executive Vice President of Commercial Operations
Oct-26-2015
(1,500)
(124,607)
26.99 - 110.06
Bischofberger Ph.D., Norbert W.
Chief Scientific Officer and Executive Vice President of Research & Development
Oct-15-2015
(70,000)
(5,350,972)
23.60 - 101.18
Milligan Ph.D., John F.
Chief Executive Officer, President and Director
Oct-07-2015
(100,000)
(8,471,274)
14.50 - 99.93
Alton, Gregg H.
Executive Vice President of Corporate & Medical Affairs and Secretary
Oct-05-2015
(5,000)
(378,525)
24.30 - 100.00
Martin Ph.D., John C.
Executive Chairman
Oct-01-2015
(150,000)
(12,446,914)
14.50 - 97.97
Alton, Gregg H.
Executive Vice President of Corporate & Medical Affairs and Secretary
Oct-01-2015
(2,000)
(195,496)
97.09 - 98.58
Alton, Gregg H.
Executive Vice President of Corporate & Medical Affairs and Secretary
Oct-01-2015
(5,000)
(363,960)
24.30 - 97.09
Carter, Paul Rutherford
Executive Vice President of Commercial Operations
Oct-01-2015
(2,000)
(118,503)
26.99 - 98.59
Private Ownership
Investor
Relationship Type
Transaction Date(s)
Company Type
Investment Coverage
Most Recent Transaction Size (USD in mm)
Most Recent Amount Invested (USD in mm)
Capital Research Global Investors
Current
-
Private Investment Firm
-
-
-
Capital World Investors
Current
-
Private Investment Firm
-
-
-
HBM Partners Ltd.
Current
-
Private Investment Firm
-
-
-
International Biotechnology Trust plc
Current
-
Public Fund
-
-
-
T. Rowe Price Associates, Inc.
Current
-
Private Investment Firm
-
-
-
Tekla Capital Management LLC
Current
Sep-10-1991
Private Investment Firm
-
20.00
-
Tekla Healthcare Investors
Current
Sep-10-1991
Public Fund
-
20.00
-
3i Group plc
Prior
-
Public Investment Firm
-
-
-
Abingworth LLP
Prior
Nov-30-1988, Sep-10-1991
Private Investment Firm
-
20.00
-
BB Biotech AG
Prior
-
Public Fund
-
-
-
Bellevue Asset Management AG
Prior
-
Private Investment Firm
-
-
-
Bio*One Capital Pte Ltd
Prior
-
Private Investment Firm
-
-
-
Concord Ventures
Prior
Sep-10-1991
Corporate Investment Arm
-
20.00
-
EDB Investments Pte. Ltd.
Prior
Sep-10-1991
Corporate Investment Arm
-
20.00
-
HBM Healthcare Investments AG
Prior
-
Public Fund
-
-
-
Health Care & Biotechnology Venture Fund
Prior
Dec-31-1992
Public Fund
-
0.14
-
J.H. Whitney & Co., LLC
Prior
Dec-31-1988, Dec-31-1988, Sep-10-1991
Private Investment Firm
-
20.00
-
John Hancock Investments
Prior
Sep-10-1991
Private Investment Firm
-
20.00
-
Lumira Capital Corp.
Prior
Dec-31-1992
Private Investment Firm
-
0.14
0.64
Menlo Ventures
Prior
Dec-31-1988, Sep-10-1991
Private Investment Firm
Henry Montgomery
20.00
-
Merrill, Pickard, Anderson & Eyre
Prior
Sep-10-1991
Private Investment Firm
-
20.00
-
SIG Holdings, Inc.
Prior
Sep-10-1991
Financial Service Investment Arm
-
20.00
-
SV Life Sciences Advisers, LLC
Prior
-
Private Investment Firm
-
-
-
Temasek Holdings (Private) Limited
Prior
-
Private Investment Firm
-
-
-
Venrock
Prior
Dec-31-1988, Sep-10-1991
Private Investment Firm
-
20.00
-
Vista Technology Group, Ltd., The
Prior
Sep-10-1991
Private Company
-
20.00
-
William Blair Capital Partners, L.L.C.
Prior
-
Private Investment Firm
-
-
-
Key Executives
Name
Title
Alton, Gregg H.
Executive Vice President of Corporate & Medical Affairs and Secretary
Belardinelli, Luiz
Senior Vice President of Cardiovascular Therapeutics
Bischofberger, Norbert W.
Chief Scientific Officer and Executive Vice President of Research & Development
Bishop, Philippe C.
Senior Vice President of Hematology and Oncology Therapeutics
Carter, Paul Rutherford
Executive Vice President of Commercial Operations
Cheng, Andrew
Executive Vice President of Clinical Research & Development Operations
Jacobson, Ira
Paid Consultant
Lange, Louis G.
Senior Advisor
Lee, William A.
Executive Vice President of Research
Martin, John C.
Executive Chairman
McHutchison, John G.
Executive Vice President of Clinical Research
Milligan, John F.
Chief Executive Officer, President and Director
Pletcher, Brett
Executive Vice President and General Counsel
Washington, Robin L.
Chief Financial Officer and Executive Vice President
Watson, Katie L.
Executive Vice President of Human Resources
Yang, Taiyin
Executive Vice President of Pharmaceutical Development and Manufacturing
Young, Kevin B.
Senior Advisor
Board Members
Name
Title
Anderson, Kenneth C. (Board)
Member of the Scientific Advisory Board
Berg, Paul (Board)
Member of Scientific Advisory Board
Chisari, Francis V. (Board)
Member of the Scientific Advisory Board
Cogan, John F. (Board)
Lead Independent Director, Member of Audit Committee and Member of Scientific Committee
Davignon, Vicomte Étienne (Board)
Independent Director and Member of Nominating & Corporate Governance Committee
Druker, Brian J. (Board)
Member of the Scientific Advisory Board
Gollaher, David L. (Board)
Member of Health Policy Advisory Board
Harrington, Robert A. (Board)
Member of the Scientific Advisory Board
Hills, Carla Anderson (Board)
Independent Director and Member of Nominating & Corporate Governance Committee
Huff, Joel R. (Board)
Chairperson of Scientific Advisory Board
Klotman, Paul E. (Board)
Member of the Scientific Advisory Board
Lofton, Kevin E. (Board)
Independent Director, Member of Audit Committee and Member of Compensation Committee
Madigan, John W. (Board)
Independent Director, Chairman of Compensation Committee and Member of Audit Committee
Martin, John C.
Executive Chairman
Mellors, John W. (Board)
Member of the Scientific Advisory Board
Milligan, John F.
Chief Executive Officer, President and Director
Moore, Nicholas G. (Board)
Independent Director, Chairman of Audit Committee and Member of Compensation Committee
Schiff, Eugene R. (Board)
Member of the Scientific Advisory Board
Schooley, Robert T. (Board)
Member of the Scientific Advisory Board
Shultz, George Pratt
Advisor and Director Emeritus
Topol, Eric J. (Board)
Member of Scientific Advisory Board
Whitley, Richard J. (Board)
Independent Director, Member of Independent Health Policy Advisory Board, Chairman of Scientific Committee and Member of Nominating & Corporate Governance Committee
Wilson, Gayle Edlund (Board)
Independent Director, Chairman of Nominating & Corporate Governance Committee and Member of Scientific Committee
Wold-Olsen, Per (Board)
Independent Director, Member of Compensation Committee and Member of Scientific Committee
Summary Public Offerings/Shelf Registrations
Announced Date
Nov-04-2015
Target
Gilead Sciences Inc. (NasdaqGS:GILD)
Status
Announced
Size (USD mm)
1,309.20 Target Advisors: Ernst & Young LLP (Accountant); Gibson, Dunn & Crutcher LLP (Legal Advisor) Synopsis: Gilead Sciences Inc. (NasdaqGS: GILD) registered 12,000,000 shares of common stock issuable pursuant to Gilead Sciences, Inc. Employee Stock Purchase Plan and Gilead Sciences, Inc. International Employee Stock Purchase Plan.Ronald O. Mueller of Gibson, Dunn & Crutcher LLP is acting as the legal advisor to the company. Pre-Deal Situation: - Deal Resolution: -
Announced Date
Sep-09-2015
Issuer
Gilead Sciences Inc. (NasdaqGS:GILD)
Status
Closed
Size (USD mm)
999.89 Issuer Advisors: Barclays Capital Inc. (Underwriter); Ernst & Young LLP (Accountant); Evercore Group L.L.C. (Underwriter); Goldman, Sachs & Co. (Underwriter); HSBC Securities (USA) Inc. (Underwriter); J. Wood Capital Advisors LLC (Financial Advisor); J.P. Morgan Securities LLC (Co-Lead Underwriter); Latham & Watkins LLP (Legal Counsel to Underwriters); Merrill Lynch, Pierce, Fenner & Smith Incorporated (Co-Lead Underwriter); Mitsubishi UFJ Securities (USA), Inc. (Underwriter); Mizuho Securities USA Inc. (Co-Lead Underwriter); Morgan Stanley & Co. LLC (Co-Lead Underwriter); RBC Capital Markets LLC (Underwriter); Skadden, Arps, Slate, Meagher & Flom LLP (Legal Advisor); SMBC Nikko Securities America, Inc. (Underwriter); The Williams Capital Group, L.P. (Underwriter); U.S. Bancorp Investments, Inc. (Underwriter); Wells Fargo Bank, National Association (Transfer Agent/Registrar); Wells Fargo Bank, National Association (Trustee); Wells Fargo Securities, LLC (Underwriter) Synopsis: Interest on the 1.850% Senior Unsecured Notes due September 4, 2018 will be payable semi-annually on March 4 and September 4 of each year, beginning on March 4, 2016.The notes will be callable anytime at a make whole premium at the treasury rate plus 12.5 basis points.The yield to maturity is 1.854%.Gilead Sciences Inc. (NasdaqGS: GILD) concurrently offered $2,000 million of 2.550% Senior Unsecured Notes due September 1, 2020, $1,000 million of 3.250% Senior Unsecured Notes due September 1, 2022, $2,750 million of 3.650% Senior Unsecured Notes due March 1, 2026, $1,000 million of 4.600% Senior Unsecured Notes due September 1, 2035 and $2,250 million of 4.750% Senior Unsecured Notes due March 1, 2046.The company intends to use a part of the net proceeds to pay offering expenses.The offering expenses amounting to $7,300,000 have been paid along with the expenses of the concurrent offering of $2,750 million of 3.650% Senior Unsecured Notes due March 1, 2026. Pre-Deal Situation: - Deal Resolution: -
Announced Date
Sep-09-2015
Issuer
Gilead Sciences Inc. (NasdaqGS:GILD)
Status
Closed
Size (USD mm)
998.59 Issuer Advisors: Barclays Capital Inc. (Underwriter); Ernst & Young LLP (Accountant); Evercore Group L.L.C. (Underwriter); Goldman, Sachs & Co. (Underwriter); HSBC Securities (USA) Inc. (Underwriter); J. Wood Capital Advisors LLC (Financial Advisor); J.P. Morgan Securities LLC (Co-Lead Underwriter); Latham & Watkins LLP (Legal Counsel to Underwriters); Merrill Lynch, Pierce, Fenner & Smith Incorporated (Co-Lead Underwriter); Mitsubishi UFJ Securities (USA), Inc. (Underwriter); Mizuho Securities USA Inc. (Co-Lead Underwriter); Morgan Stanley & Co. LLC (Co-Lead Underwriter); RBC Capital Markets LLC (Underwriter); Skadden, Arps, Slate, Meagher & Flom LLP (Legal Advisor); SMBC Nikko Securities America, Inc. (Underwriter); The Williams Capital Group, L.P. (Underwriter); U.S. Bancorp Investments, Inc. (Underwriter); Wells Fargo Bank, National Association (Transfer Agent/Registrar); Wells Fargo Bank, National Association (Trustee); Wells Fargo Securities, LLC (Underwriter) Synopsis: Interest on the 3.250% Senior Unsecured Notes due September 1, 2022 will be payable semi-annually on March 1 and September 1 of each year, beginning on March 1, 2016.The notes will be callable anytime at a make whole premium prior to July 1, 2022 at the treasury rate plus 20 basis points. The notes will be callable on or after July 1, 2022 at par.The yield to maturity is 3.273%.Gilead Sciences Inc. (NasdaqGS: GILD) concurrently offered $2,000 million of 2.550% Senior Unsecured Notes due September 1, 2020, $1,000 million of 1.850% Senior Unsecured Notes due September 4, 2018, $2,750 million of 3.650% Senior Unsecured Notes due March 1, 2026, $1,000 million of 4.600% Senior Unsecured Notes due September 1, 2035 and $2,250 million of 4.750% Senior Unsecured Notes due March 1, 2046.The company intends to use a part of the net proceeds to pay offering expenses.The offering expenses amounting to $7,300,000 have been paid along with the expenses of the concurrent offering of $2,750 million of 3.650% Senior Unsecured Notes due March 1, 2026. Pre-Deal Situation: - Deal Resolution: -
Announced Date
Sep-09-2015
Issuer
Gilead Sciences Inc. (NasdaqGS:GILD)
Status
Closed
Size (USD mm)
2,738.89 Issuer Advisors: Barclays Capital Inc. (Co-Lead Underwriter); Ernst & Young LLP (Accountant); Evercore Group L.L.C. (Underwriter); Goldman, Sachs & Co. (Co-Lead Underwriter); HSBC Securities (USA) Inc. (Underwriter); J. Wood Capital Advisors LLC (Financial Advisor); J.P. Morgan Securities LLC (Co-Lead Underwriter); Latham & Watkins LLP (Legal Counsel to Underwriters); Merrill Lynch, Pierce, Fenner & Smith Incorporated (Co-Lead Underwriter); Mitsubishi UFJ Securities (USA), Inc. (Underwriter); Mizuho Securities USA Inc. (Underwriter); Morgan Stanley & Co. LLC (Underwriter); RBC Capital Markets LLC (Underwriter); Skadden, Arps, Slate, Meagher & Flom LLP (Legal Advisor); SMBC Nikko Securities America, Inc. (Underwriter); The Williams Capital Group, L.P. (Underwriter); U.S. Bancorp Investments, Inc. (Underwriter); Wells Fargo Bank, National Association (Transfer Agent/Registrar); Wells Fargo Bank, National Association (Trustee); Wells Fargo Securities, LLC (Underwriter) Synopsis: Interest on the 3.650% Senior Unsecured Notes due March 1, 2026 will be payable semi-annually on March 1 and September 1 of each year, beginning on March 1, 2016.The notes will be callable prior to December 1, 2025 at a make whole premium at the treasury rate plus 25 basis points. The notes will be callable on or after December 1, 2025 at par.The yield to maturity is 3.697%.Gilead Sciences Inc. (NasdaqGS: GILD) concurrently offered $2,000 million of 2.550% Senior Unsecured Notes due September 1, 2020, $1,000 million of 3.250% Senior Unsecured Notes due September 1, 2022, $1,000 million of 1.850% Senior Unsecured Notes due September 4, 2018, $1,000 million of 4.600% Senior Unsecured Notes due September 1, 2035 and $2,250 million of 4.750% Senior Unsecured Notes due March 1, 2046.The company intends to use a part of the net proceeds to pay offering expenses.The offering expenses amounting to 7,300,000 include the expenses incurred for the concurrent offering of $2,000 million of 2.550% Senior Unsecured Notes due September 1, 2020, $1,000 million of 3.250% Senior Unsecured Notes due September 1, 2022, $1,000 million of 1.850% Senior Unsecured Notes due September 4, 2018, $1,000 million of 4.600% Senior Unsecured Notes due September 1, 2035 and $2,250 million of 4.750% Senior Unsecured Notes due March 1, 2046. Pre-Deal Situation: - Deal Resolution: -
Announced Date
Sep-09-2015
Issuer
Gilead Sciences Inc. (NasdaqGS:GILD)
Status
Closed
Size (USD mm)
996.65 Issuer Advisors: Barclays Capital Inc. (Underwriter); Ernst & Young LLP (Accountant); Evercore Group L.L.C. (Underwriter); Goldman Sachs Bank AG (Underwriter); HSBC Securities (USA) Inc. (Co-Lead Underwriter); J. Wood Capital Advisors LLC (Financial Advisor); J.P. Morgan Securities LLC (Co-Lead Underwriter); Latham & Watkins LLP (Legal Counsel to Underwriters); Merrill Lynch, Pierce, Fenner & Smith Incorporated (Co-Lead Underwriter); Mitsubishi UFJ Securities (USA), Inc. (Underwriter); Mizuho Securities USA Inc. (Underwriter); Morgan Stanley & Co. LLC (Underwriter); RBC Capital Markets LLC (Underwriter); Skadden, Arps, Slate, Meagher & Flom LLP (Legal Advisor); SMBC Nikko Securities America, Inc. (Underwriter); The Williams Capital Group, L.P. (Underwriter); U.S. Bancorp Investments, Inc. (Underwriter); Wells Fargo Bank, National Association (Transfer Agent/Registrar); Wells Fargo Bank, National Association (Trustee); Wells Fargo Securities, LLC (Co-Lead Underwriter) Synopsis: Interest on the 4.600% Senior Unsecured Notes due September 1, 2035 will be payable semi-annually on March 1 and September 1 of each year, beginning on March 1, 2016.The notes will be callable prior to March 1, 2035 at a make whole premium at the treasury rate plus 25 basis points. The notes will be callable on or after March 1, 2035 at par.The yield to maturity is 4.626%.Gilead Sciences Inc. (NasdaqGS: GILD) concurrently offered $2,000 million of 2.550% Senior Unsecured Notes due September 1, 2020, $1,000 million of 3.250% Senior Unsecured Notes due September 1, 2022, $2,750 million of 3.650% Senior Unsecured Notes due March 1, 2026, $1,000 million of 1.850% Senior Unsecured Notes due September 4, 2018 and $2,250 million of 4.750% Senior Unsecured Notes due March 1, 2046.The company intends to use a part of the net proceeds to pay offering expenses.The offering expenses amounting to $7,300,000 have been paid along with the expenses of the concurrent offering of $2,750 million of 3.650% Senior Unsecured Notes due March 1, 2026. Pre-Deal Situation: - Deal Resolution: -
Key Developments
Key Developments
Gilead Sciences Inc. Presents at Barclays Global Healthcare Conference, Mar-15-2016 09:00 AM
Gilead Sciences Inc. (NasdaqGS:GILD)
Mar-15-2016 09:00 AM
Company Conference Presentation
Situation: Gilead Sciences Inc. Presents at Barclays Global Healthcare Conference, Mar-15-2016 09:00 AM. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami Beach, Florida, United States. Speakers: John F. Milligan, President and Chief Operating Officer. Source: PR Newswire; Business Wire; GlobeNewswire; Company Website; Market News Publishing; Thomson Reuters ONE
Barclays Capital PLC, Barclays Global Healthcare Conference, Mar 15, 2016 through Mar 17, 2016
Gilead Sciences Inc. (NasdaqGS:GILD)
Mar-15-2016
Conference
Situation: Barclays Capital PLC, Barclays Global Healthcare Conference, Mar 15, 2016 through Mar 17, 2016. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami Beach, Florida, United States. Source: PR Newswire; Business Wire; GlobeNewswire; Company Website; Market News Publishing; Thomson Reuters ONE
Gilead Sciences Inc., $ 0.43, Cash Dividend, Mar-14-2016
Gilead Sciences Inc. (NasdaqGS:GILD)
Mar-14-2016
Ex-Div Date (Regular)
Situation: Gilead Sciences Inc., $ 0.43, Cash Dividend, Mar-14-2016 Source: Financial Times
Gilead Sciences Inc. Presents at Cowen and Company 36th Annual Health Care Conference, Mar-07-2016 01:20 PM
Gilead Sciences Inc. (NasdaqGS:GILD)
Mar-07-2016 01:20 PM
Company Conference Presentation
Situation: Gilead Sciences Inc. Presents at Cowen and Company 36th Annual Health Care Conference, Mar-07-2016 01:20 PM. Venue: Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Paul Rutherford Carter, Executive Vice President of Commercial Operations. Source: PR Newswire; Business Wire; GlobeNewswire; M2 Presswire; Company Website; Market News Publishing
Cowen and Company, LLC, Cowen and Company 36th Annual Health Care Conference, Mar 07, 2016 through Mar 09, 2016
Gilead Sciences Inc. (NasdaqGS:GILD)
Mar-07-2016
Conference
Situation: Cowen and Company, LLC, Cowen and Company 36th Annual Health Care Conference, Mar 07, 2016 through Mar 09, 2016. Venue: Boston Marriott Copley Place, Boston, Massachusetts, United States. Source: PR Newswire; Business Wire; GlobeNewswire; M2 Presswire; Company Website; Market News Publishing
Gilead Sciences Inc. Presents at 10th Annual Daiwa Investment Conference 2016, Mar-02-2016 03:00 PM
Gilead Sciences Inc. (NasdaqGS:GILD)
Mar-02-2016 01:00 AM
Company Conference Presentation
Situation: Gilead Sciences Inc. Presents at 10th Annual Daiwa Investment Conference 2016, Mar-02-2016 03:00 PM. Venue: The Prince Park Tower, Tokyo, Japan. Speakers: Robin L. Washington, Chief Financial Officer and Executive Vice President. Source: Company Website
U.S. Food and Drug Administration Approves Gilead Sciences, Inc.’s Odefsey® for the Treatment of HIV-1 Infection
Gilead Sciences Inc. (NasdaqGS:GILD)
Mar-01-2016 02:06 PM
Product-Related Announcement
Situation: Gilead Sciences Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Odefsey® (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the treatment of HIV-1 infection in certain patients. Emtricitabine and tenofovir alafenamide are from Gilead Sciences and rilpivirine is from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). Odefsey is Gilead’s second TAF-based regimen to receive FDA approval and represents the smallest pill of any single tablet regimen for the treatment of HIV. Odefsey is indicated as a complete regimen for the treatment of HIV-1 infection in patients 12 years of age and older who have no antiretroviral treatment history and HIV-1 RNA levels less than or equal to 100,000 copies per mL. Odefsey is also indicated as replacement for a stable antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) for at least six months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Odefsey. No dosage adjustment of Odefsey is required in patients with estimated creatinine clearance greater than or equal to 30 mL per minute. Odefsey has a boxed warningin its product label regarding the risks of lactic acidosis/severe hepatomegaly with steatosis, and post treatment acute exacerbation of hepatitis B. See below for important safety information. TAF is a novel targeted prodrug of tenofovir that has demonstrated high antiviral efficacy similar to and at a dose less than one-tenth that of Gilead’s Viread® (tenofovir disoproxil fumarate, TDF). TAF has also demonstrated improvement in surrogate laboratory markers of renal and bone safety as compared to TDF in clinical trials in combination with other antiretroviral agents. Data show that because TAF enters cells, including HIV-infected cells, more efficiently than TDF, it can be given at a much lower dose and there is 90% less tenofovir in the bloodstream. The approval is supported by a bioequivalence study demonstrating that Odefsey achieved similar drug levels of emtricitabine and TAF in the blood as Genvoya® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg or E/C/F/TAF) and similar drug levels of rilpivirine as Edurant® (rilpivirine 25 mg). The safety, efficacy and tolerability of Odefsey is supported by clinical studies of rilpivirine-based therapy (administered as R+F/TDF or R/F/TDF) and F/TAF-based therapy (administered as E/C/F/TAF) in a range of patients with HIV, including treatment-naïve adults and adolescents, virologically suppressed adults who switched from PI-, NNRTI- and INSTI-based regimens and virologically suppressed adults with mild-to-moderate renal impairment. The Odefsey approval is part of an ongoing development and commercialization agreement between Gilead and Janssen, first established in 2009. Under this agreement, Gilead is responsible for the manufacturing, registration, distribution and commercialization of the product in most countries, while Janssen will distribute it in approximately 17 markets and have co-detailing rights in several key markets, including the United States. The original agreement was established for the development and commercialization of Complera®, marketed as Eviplera® in the European Union, and expanded in 2014 to include Odefsey. Odefsey does not cure HIV infection or AIDS. Gilead’s U.S. Advancing Access® program provides assistance to appropriate patients in the United States who are uninsured, underinsured or who need financial assistance to pay for their medications, including Odefsey. The program offers information and assistance for patients, including: Access to agents who can provide information related to coverage and insurance-related questions; The Advancing Access Copay Coupon Program, which provides co-pay assistance for eligible patients with private insurance who need assistance paying for out-of-pocket medication costs; The Advancing Access Patient Assistance Program and Truvada®Medication Assistance Program, which will provide Gilead medications at no charge for eligible patients with no other insurance options; Additionally, Gilead is working closely with the ADAP Crisis Task Force, as the company has done for each of its other HIV medications, to provide discounts to state AIDS Drug Assistance Programs (ADAPs) that will help ensure access to Odefsey for patients who receive medications through these programs. Source: Business Wire
Daiwa Securities Co., Ltd., 10th Annual Daiwa Investment Conference 2016, Feb 29, 2016 through Mar 04, 2016
Gilead Sciences Inc. (NasdaqGS:GILD)
Feb-28-2016 10:00 AM
Conference
Situation: Daiwa Securities Co., Ltd., 10th Annual Daiwa Investment Conference 2016, Feb 29, 2016 through Mar 04, 2016. Venue: The Prince Park Tower, Tokyo, Japan. Source: Company Website
European Medicines Agency Validates Gilead’s Marketing Application for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B
Gilead Sciences Inc. (NasdaqGS:GILD)
Feb-25-2016 10:37 AM
Product-Related Announcement
Situation: Gilead Sciences Inc. announced that the company’s Marketing Authorization Application (MAA) for tenofovir alafenamide (as fumarate) (TAF) 25 mg – an investigational, once-daily treatment for adults with chronic hepatitis B virus (HBV) infection – has been fully validated and is now under assessment by the European Medicines Agency (EMA). The MAA for TAF is supported by 48-week data from two Phase 3 studies which met their primary objective of non-inferiority in efficacy (HBV DNA < 29 IU/mL at week 48)compared to TDF among treatment-naïve and treatment-experienced adults with HBeAg-negative and HBeAg-positive chronic HBV. In both studies, treatment with TAF showed a statistically significant increase in serum alanine aminotransferase normalization relative to the TDF arms when using the American Association for the Study of Liver Disease criteria. Changes in renal and bone laboratory safety parameters favored the TAF treatment regimen. Overall, patients receiving TAF experienced a significantly smaller mean percentage decrease from baseline in hip and spine bone mineral density at week 48 compared to patients receiving TDF. Additionally, the overall median change in serum creatinine from baseline to week 48 favored TAF. Rates of discontinuations due to adverse events and the most commonly reported adverse events were similar in patients receiving TAF or TDF. TAF for the treatment of HBV will be reviewed by the EMA under the centralized licensing procedure which, if authorized, provides marketing authorization in all 28 member states of the European Union, Norway and Iceland. Gilead also submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for TAF on January 11, 2016. TAF as a single agent treatment for HBV is an investigational product and its safety and efficacy have not been established. Source: Business Wire
Gilead Sciences Inc. Announces Data from New Preclinical Study Evaluating an Investigational TLR7 Agonist in SIV-Infected Monkeys
Gilead Sciences Inc. (NasdaqGS:GILD)
Feb-24-2016 12:09 PM
Product-Related Announcement
Situation: Gilead Sciences Inc. announced results from a preclinical study conducted in collaboration with researchers at Beth Israel Deaconess Medical Center evaluating a proprietary investigational oral toll-like receptor 7 (TLR7) agonist, GS-9620, and a related molecular analogue, GS-986, as part of an HIV eradication strategy. Data from the study conducted in simian immunodeficiency virus (SIV)-infected virally suppressed rhesus macaques on antiretroviral therapy (ART) demonstrate that TLR7 agonist treatment induced transient plasma SIV RNA blips and reduced SIV DNA. In addition, TLR7 agonist treatment resulted in subsequent prolonged virus suppression in some of the macaques after stopping ART. Earlier research presented at CROI 2015 showed that GS-986 treatment, in combination with ART, reduced SIV DNA levels by 30% to 90% in some tissues. This follow-up study was designed to assess whether GS-9620 produced results similar to GS-986, and whether lower doses of the compounds would induce transient plasma viremia and/or perturb SIV viral reservoirs. A lower dose was chosen with the intent to minimize induction of peripheral interferon-alpha (IFN-alpha), an anti-viral protein that can cause adverse events. In this placebo-controlled study, SIV-infected rhesus macaques received ART beginning day 65 post-infection. All animals achieved and maintained viral suppression (plasma RNA less than 50 copies/mL) through week 67 when they received 10 to 19 doses of either GS-9620 or GS-986 every other week. TLR7 agonist dosing induced transient and variable increases in plasma SIV RNA levels across all treatment groups. After completing all doses of TLR7 agonist and prior to stopping ART, peripheral lymphocytes and lymph node biopsies from the animals had less inducible virus. Two of the TLR7 agonist-treated rhesus macaques maintained undetectable plasma viral load for more than 90 days after stopping ART. The proprietary TLR7 agonist compounds GS-9620 and GS-986 are investigational agents, and their safety and efficacy have not been established. Source: Business Wire
Auditors
Period Audited
Auditor
Opinion
Auditor Parent
FY 2015
Ernst & Young LLP
Unqualified
Ernst & Young LLP
FY 2014
Ernst & Young LLP
Unqualified
Ernst & Young LLP
Transaction Advisors
Accounting Advisors
Advisor
No. of Transactions
Total Value Disclosed (USD mm)
Most Recent Transaction Date
Ernst & Young LLP
32
27,800.89
Nov-04-2015
Transaction Dates: Nov-04-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Mar-23-2011 (Gilead Sciences Inc.), Mar-23-2011 (Gilead Sciences Inc.), Jan-31-2011 (Gilead Sciences Inc.), Dec-18-2009 (Gilead Sciences Inc.), Aug-05-2009 (Gilead Sciences Inc.), Apr-17-2009 (Gilead Sciences Inc.), Jun-12-2008 (Gilead Sciences Inc.), Jun-20-2007 (Gilead Sciences Inc.), Nov-28-2006 (Gilead Sciences Inc.), Dec-22-2003 (Gilead Sciences Inc.), Mar-17-2003 (Gilead Sciences Inc.), Jan-26-2001 (Gilead Sciences Inc.), Sep-15-1999 (Gilead Sciences Inc.), Mar-01-1999 (NeXstar Pharmaceuticals, Inc.)
Wells Fargo Bank, National Association
17
22,635.18
Sep-09-2015
Transaction Dates: Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Mar-23-2011 (Gilead Sciences Inc.)
Computershare Shareowner Services LLC
4
516.92
Mar-04-2014
Transaction Dates: Mar-04-2014 (Gilead Sciences Inc.), Mar-23-2011 (Gilead Sciences Inc.), Nov-28-2006 (Gilead Sciences Inc.), Dec-22-2003 (Gilead Sciences Inc.)
PricewaterhouseCoopers LLP
2
595.00
Mar-17-2003
Transaction Dates: Mar-17-2003 (Gilead Sciences Inc.), Jan-26-2001 (Gilead Sciences Inc.)
Administrative Advisors
Advisor
No. of Transactions
Total Value Disclosed (USD mm)
Most Recent Transaction Date
Innisfree M&A Inc.
2
12,663.42
Nov-21-2011
Transaction Dates: Nov-21-2011 (Gilead Pharmasset LLC), Mar-12-2009 (Gilead Palo Alto, Inc.)
Computershare Shareowner Services LLC
1
11,011.70
Nov-21-2011
Transaction Dates: Nov-21-2011 (Gilead Pharmasset LLC)
Financial Advisors
Advisor
No. of Transactions
Total Value Disclosed (USD mm)
Most Recent Transaction Date
J.P. Morgan Securities LLC
22
26,238.82
Sep-09-2015
Transaction Dates: Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Mar-23-2011 (Gilead Sciences Inc.), Jul-26-2010 (Gilead Sciences Inc.), Nov-26-2001 (Gilead Sciences, Oncology Assets), Dec-11-2000 (Gilead Sciences Inc.), Mar-01-1999 (NeXstar Pharmaceuticals, Inc.), Jan-23-1996 (Gilead Sciences Inc.)
Goldman, Sachs & Co.
19
25,200.41
Sep-09-2015
Transaction Dates: Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Jul-26-2010 (Gilead Sciences Inc.), Apr-18-2006 (Gilead Sciences Inc.), Dec-12-2002 (Gilead Sciences Inc.), Dec-03-2002 (Triangle Pharmaceuticals, Inc.)
Merrill Lynch, Pierce, Fenner & Smith Incorporated
19
34,924.13
Sep-09-2015
Transaction Dates: Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Nov-21-2011 (Gilead Pharmasset LLC), Mar-23-2011 (Gilead Sciences Inc.), Apr-18-2006 (Gilead Sciences Inc.)
Barclays Capital Inc.
18
33,646.88
Sep-09-2015
Transaction Dates: Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Nov-21-2011 (Gilead Pharmasset LLC), Mar-23-2011 (Gilead Sciences Inc.)
RBC Capital Markets LLC
16
21,643.76
Sep-09-2015
Transaction Dates: Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.)
Mizuho Securities USA Inc.
16
21,643.76
Sep-09-2015
Transaction Dates: Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.)
Wells Fargo Securities, LLC
16
21,643.76
Sep-09-2015
Transaction Dates: Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.)
HSBC Securities (USA) Inc.
16
21,643.76
Sep-09-2015
Transaction Dates: Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.)
U.S. Bancorp Investments, Inc.
16
21,643.76
Sep-09-2015
Transaction Dates: Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.)
Mitsubishi UFJ Securities (USA), Inc.
16
21,643.76
Sep-09-2015
Transaction Dates: Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.)
Morgan Stanley & Co. LLC
12
16,482.72
Sep-09-2015
Transaction Dates: Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-23-2011 (Gilead Sciences Inc.), Apr-18-2006 (Gilead Sciences Inc.), Dec-11-2000 (Gilead Sciences Inc.)
SMBC Nikko Securities America, Inc.
12
17,950.99
Sep-09-2015
Transaction Dates: Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.)
The Williams Capital Group, L.P.
9
13,958.07
Sep-09-2015
Transaction Dates: Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.)
Evercore Group L.L.C.
6
9,971.13
Sep-09-2015
Transaction Dates: Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.)
J. Wood Capital Advisors LLC
6
9,971.13
Sep-09-2015
Transaction Dates: Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.)
Goldman Sachs Bank AG
1
996.65
Sep-09-2015
Transaction Dates: Sep-09-2015 (Gilead Sciences Inc.)
SMBC Nikko Capital Markets Limited
4
3,692.77
Dec-06-2011
Transaction Dates: Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.)
Leerink Partners LLC
2
3,453.92
Mar-23-2011
Transaction Dates: Mar-23-2011 (Gilead Sciences Inc.), Jul-26-2010 (Gilead Sciences Inc.)
Deutsche Bank Securities Inc.
1
991.42
Mar-23-2011
Transaction Dates: Mar-23-2011 (Gilead Sciences Inc.)
Credit Suisse Securities (USA) LLC
1
991.42
Mar-23-2011
Transaction Dates: Mar-23-2011 (Gilead Sciences Inc.)
Merrill Lynch & Co., Inc.
1
1,651.72
Mar-12-2009
Transaction Dates: Mar-12-2009 (Gilead Palo Alto, Inc.)
Lazard Frères & Co. LLC
1
2,423.44
Oct-02-2006
Transaction Dates: Oct-02-2006 (Gilead Colorado, Inc.)
Lazard Ltd.
2
390.00
Jul-20-2006
Transaction Dates: Jul-20-2006 (Corus Pharma, Inc.), Apr-12-2006 (Corus Pharma, Inc.)
Banc of America Securities LLC
1
1,277.25
Apr-18-2006
Transaction Dates: Apr-18-2006 (Gilead Sciences Inc.)
Chase Securities, Inc.
1
250.00
Dec-11-2000
Transaction Dates: Dec-11-2000 (Gilead Sciences Inc.)
Lehman Brothers Inc.
1
250.00
Dec-11-2000
Transaction Dates: Dec-11-2000 (Gilead Sciences Inc.)
J.P. Morgan & Co. Inc.
1
540.15
Mar-01-1999
Transaction Dates: Mar-01-1999 (NeXstar Pharmaceuticals, Inc.)
Bear, Stearns & Co. Inc.
1
540.15
Mar-01-1999
Transaction Dates: Mar-01-1999 (NeXstar Pharmaceuticals, Inc.)
Chase H&Q
5
393.46
Jan-23-1996
Transaction Dates: Jan-23-1996 (Gilead Sciences Inc.), Jul-14-1995 (Gilead Sciences Inc.), Dec-11-1992 (Gilead Sciences Inc.), Dec-16-1991 (Gilead Sciences Inc.), Jan-06-1991 (Gilead Sciences Inc.)
FleetBoston Robertson Stephens, Inc.
5
393.46
Jan-23-1996
Transaction Dates: Jan-23-1996 (Gilead Sciences Inc.), Jul-14-1995 (Gilead Sciences Inc.), Dec-11-1992 (Gilead Sciences Inc.), Dec-16-1991 (Gilead Sciences Inc.), Jan-06-1991 (Gilead Sciences Inc.)
Pacific Growth Equities, LLC
1
151.00
Jan-23-1996
Transaction Dates: Jan-23-1996 (Gilead Sciences Inc.)
Legal Advisors
Advisor
No. of Transactions
Total Value Disclosed (USD mm)
Most Recent Transaction Date
Gibson, Dunn & Crutcher LLP
1
1,309.20
Nov-04-2015
Transaction Dates: Nov-04-2015 (Gilead Sciences Inc.)
Skadden, Arps, Slate, Meagher & Flom LLP
20
33,646.88
Sep-09-2015
Transaction Dates: Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Nov-21-2011 (Gilead Pharmasset LLC), Mar-23-2011 (Gilead Sciences Inc.), Mar-23-2011 (Gilead Sciences Inc.)
Wells Fargo Bank, National Association
20
22,652.10
Sep-09-2015
Transaction Dates: Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Mar-23-2011 (Gilead Sciences Inc.), Mar-23-2011 (Gilead Sciences Inc.), Nov-28-2006 (Gilead Sciences Inc.)
Latham & Watkins LLP
19
23,929.35
Sep-09-2015
Transaction Dates: Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Sep-09-2015 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Nov-12-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Mar-04-2014 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Dec-06-2011 (Gilead Sciences Inc.), Mar-23-2011 (Gilead Sciences Inc.), Nov-28-2006 (Gilead Sciences Inc.), Apr-18-2006 (Gilead Sciences Inc.)
Wilson Sonsini Goodrich & Rosati, Professional Corporation
1
482.87
Dec-12-2012
Transaction Dates: Dec-12-2012 (YM BioSciences Inc.)
Blake, Cassels & Graydon LLP
1
482.87
Dec-12-2012
Transaction Dates: Dec-12-2012 (YM BioSciences Inc.)
Herbert Smith Freehills LLP
1
482.87
Dec-12-2012
Transaction Dates: Dec-12-2012 (YM BioSciences Inc.)
Morgan, Lewis & Bockius LLP
3
405.29
Jan-31-2011
Transaction Dates: Jan-31-2011 (Gilead Sciences Inc.), Apr-17-2009 (Gilead Sciences Inc.), Jun-20-2007 (Gilead Sciences Inc.)
Covington & Burling LLP
1
120.00
Jun-25-2010
Transaction Dates: Jun-25-2010 (CGI Pharmaceuticals, Inc.)
Cooley LLP
14
8,469.70
Mar-12-2009
Transaction Dates: Mar-12-2009 (Gilead Palo Alto, Inc.), Jun-12-2008 (Gilead Sciences Inc.), Jun-20-2007 (Gilead Sciences Inc.), Oct-02-2006 (Gilead Colorado, Inc.), Jul-20-2006 (Corus Pharma, Inc.), Dec-22-2003 (Gilead Sciences Inc.), Mar-17-2003 (Gilead Sciences Inc.), Dec-12-2002 (Gilead Sciences Inc.), Dec-03-2002 (Triangle Pharmaceuticals, Inc.), Nov-26-2001 (Gilead Sciences, Oncology Assets), Jan-26-2001 (Gilead Sciences Inc.), Dec-11-2000 (Gilead Sciences Inc.), Sep-15-1999 (Gilead Sciences Inc.), Mar-01-1999 (NeXstar Pharmaceuticals, Inc.)
Cahill Gordon & Reindel LLP
1
250.00
Jan-26-2001
Transaction Dates: Jan-26-2001 (Gilead Sciences Inc.)
Jones Day
1
540.15
Mar-01-1999
Transaction Dates: Mar-01-1999 (NeXstar Pharmaceuticals, Inc.)
Richards, Layton & Finger, P.A.
1
540.15
Mar-01-1999
Transaction Dates: Mar-01-1999 (NeXstar Pharmaceuticals, Inc.)
News
3 Large-Cap Stocks With the Highest Net Profit Margins [FOX Business Network]
FOX Business Network Mar-21-2016 12:44 PM Image source: Pictures of Money via Flickr.
New and generic drug approvals: Viread, oral tablet, Gilead SciencesInc (manufacturing change or addition). [1 table in original article]
US Food and Drug Administration News (CBNB Abstracts) Mar-21-2016 05:36 AMOn 10 Mar 2016, the US Food and Drug Administration announcedapproval of NDA 021356 for Viread, oral tablet. The product containstenofovir disoproxil fumarate 300 mg, 150 mg, 200 mg, or 250 mg (4formulations), is manufactured by Gilead Sciences Inc, and is prescriptiononly. There is 1 therapeutic equivalent for the 300 mg formulation (data intherapeutic equivalents tables). Original Source: US Food and DrugAdministration, http://www.fda.gov.
New and generic drug approvals: Complera, oral tablet, Gilead SciencesInc (manufacturing change or addition).
US Food and Drug Administration News (CBNB Abstracts) Mar-19-2016 05:01 PM On 9 Mar 2016, the US Food and Drug Administration announcedapproval of NDA 202123 for Complera, oral tablet. The product containsemtricitabine 200 mg, rilpivirine hydrochloride 25 mg (eq base), andtenofovir disoproxil fumarate 300 mg (1 formulation), is manufactured byGilead Sciences Inc, and is prescription only. There are no therapeuticequivalents. Original Source: US Food and Drug Administration,http://www.fda.gov.
NZ scientist proves new drug to be a 'silver bullet' for Hepatitis C – so why isn't it available to other Kiwis? [Stuff]
Stuff (New Zealand) Mar-19-2016 01:13 PM A New Zealand doctor has been running innovative drug trials that have given selected patients like Sarah the chance of a new life. But for the rest of the estimated 50,000 New Zealanders living with Hep C, there's still a long wait ahead for these drugs to be approved and then publicly funded.
Leerink Partner Equities Analysts Decrease Earnings Estimates for Gilead Sciences, Inc. (GILD) [sleekmoney]
Sleek Money Mar-18-2016 07:41 PM Gilead Sciences, Inc.– Equities research analysts at Leerink Partner dropped their FY2017 earnings per share estimates for shares of Gilead Sciences in a research note issued on Wednesday, according to Zacks Investment Research. Leerink Partner analyst G. Porges now anticipates that t
Sprott Inc. Takes Position in Gilead Sciences, Inc. (GILD) [Ticker Report]
Ticker Report Mar-18-2016 05:12 PM Sprott Inc. bought a new position in shares of Gilead Sciences, Inc. during the fourth quarter, according to its most recent 13 F filing with the SEC. The fund bought 45,000 shares of the biopharmaceutical company’ s stock, valued at approximately $4,554,000. Other hedge funds have also
Results from 10-week analysis of Phase 2 study with filgotinib in Crohn's Disease presented at ECCO [Pipeline Review]
Pipeline Review (Germany) Mar-18-2016 01:07 PM Results from 10- week analysis of Phase 2 study with filgotinib in Crohn's Disease presented at ECCO
Cancer Troubles Make Gilead Sciences Acquisition More Urgent than Ever [Bidness Etc.]
Bidness Etc. Mar-18-2016 11:34 AMGilead Sciences, Inc.’ s foray into the lucrative cancer market keeps on getting harder. Barely a week after serious safety concerns, including deaths, were associated with the biotech’ s only approved cancer product, we learn that the recently hired executive, heading its cancer drug de
Potent Value In This Large-Cap ETF
Benzinga Lightning Feed Mar-18-2016 08:21 AM Last year, the value factor was plagued by the Federal Reserve. Financial services and utilities names were value residents and those sectors have been hampered by speculation regarding when the Fed would raise interest rates or if the central bank can even make that move. When Treasury yields climbed, financials got a lift, but utilities were hampered. The opposite was true when yields fell, but the result was less-than-impressive performances for sector ETFs tracking financials services and utilities stocks. Well, in this space we forecast the resurgence of the value factor and the relevant exchange traded funds. That resurgence has been on display this year as investors are eschewing growth and momentum for value. Interestingly, data suggest investors have grown tired of waiting for the value factor's resurgence. “In fact, there is evidence that some value investors are beginning to capitulate after years of watching growth outperform,” said Morningstar. Related Link: Paying Defense Pays With This Dividend ETF Looking At The Data Data show “trailing 12-month flows of investor capital into and out of value, growth, and blend mutual funds and ETFs across large-, mid-, and small-cap stocks dating back to the beginning of 1994. As of the middle of 2015, the trend turned negative for value funds, perhaps signaling that after nearly a decade of underperformance, value investors are throwing in the towel,” according to the research firm. The PowerShares Dynamic Large Cap Value Portfolio (NYSE: PWV) is one of he competitors in a crowded field of value ETFs. PWV follows an index that “is designed to provide capital appreciation while maintaining consistent stylistically accurate exposure. The Style Intellidexes apply a rigorous 10 factor style isolation process to objectively segregate companies into their appropriate investment style and size universe,” according to PowerShares. Closer Look At PWV Among value ETFs, PWV is a concentrated offering with just 50 holdings. Although the utilities sector is considered by many to be richly valued, the groups is PWV's fourth-largest sector weight at 11.5 percent. Consumer stocks, both discretionary and staples, are also viewed as expensive relative to the broader market, but those sectors combine for just over 10 percent of PWV's lineup. The $983.1 million ETF underscores the value's factors 2016 reclamation project as it is higher by more than three percent, well ahead of the S&P 500. Investors would do well to get involved before PWV takes off too much. “This is how it plays out in practice: Fed up with years of underperformance, value investors will flee value funds and drive up prices elsewhere only to subsequently come down with a case of buyer's remorse as their new funds of choice disappoint. Value will inevitably rebound, and those 'value' investors will invariably chase performance back in the same direction they came from,” adds Morningstar. PWV's top 10 holdings include Chevron Corporation (NYSE: CVX), Oracle Corporation (NYSE: ORCL) and Gilead Sciences, Inc. (NASDAQ: GILD).
WestEnd Advisors LLC Increases Stake in Gilead Sciences, Inc. (GILD) [sleekmoney]
Sleek Money Mar-17-2016 05:40 PM WestEnd Advisors LLC boosted its stake in shares of Gilead Sciences, Inc. by 2.2% during the fourth quarter, according to its most recent 13 F filing with the Securities and Exchange Commission. The fund owned 958,376 shares of the biopharmaceutical company’ s stock after buying an
* denotes proprietary relationship information.
Historical Equity Pricing Data supplied by
Regulatory News Service data provided by
